SHL TeleMedicine Ltd

SHL Telemedicine Ltd. engages in the development and market of advanced personal telemedicine solutions, which focuses on cardiovascular and related diseases. Its products and solutions include congestive heart failure, chronic obstructive pulmonary disease and cardiac monitoring services. It operates through the following geographical segments: Israel, Europe principally Germany, and Rest of the World. The company was founded by Yoram Alroy and Elon Shalev in 1987 and is headquartered in Tel Aviv, Israel.

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has announced today that it has appointed Mr. David Arnon as CEO of the Company. He will join SHL Telemedicine and assume the role on August 6, 2024, succeeding Erez Nachtomy, who, as previously announced, will step down as CEO. Mr. Arnon has over 17 years of commercial and executive level managem.

SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has clarified today that it is in discussions with Discount Capital Ltd. the investment arm of Israel Discount Bank, regarding a possible investment relating to SHL's Israeli activity. At this point, the parties have not yet taken any decision nor entered into any binding obligation with regard to.

SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is proud to announce that it has expanded its offering in Israel to include the groundbreaking ability to perform at-home Biomarker blood tests. This diagnostic tool is designed to rapidly identify cardiac markers for detection of a heart attack, transforming emergency cardiac care with sp.

SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

TEL AVIV, Israel & ZURICH, & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is thrilled to announce that it recently officially launched it's SmartHeart® membership program in the US. This announcement comes after the highly successful soft launch that was announced in November 2023, which exceeded the company's expectations, demonstrating substantial demand and.

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation. In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength. SHL's Israel operatio.

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial. The randomized clinical trial showcased, among other things, how SHL's SmartHeart® 12-lead ECG technology can significantly reduce hospital readmissions and ED visits for post-MI (heart attack) pa.

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions is pleased to share that in a remarkable display of innovation and operational excellence, the Company's SmartHeart®, portable 12-lead ECG technology showcased its unparalleled capabilities and successfully participated in Project Convergence – Capstone 4 (PC-C4), the largest, two-phase, “i.

SHL Telemedicine's SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET. The conference call for investors, journalists, and analysts to discuss the annual results 2023 will be hosted by Yariv Alroy, Chairman, Erez Nachtomy, CEO, and Amir Hai, CFO,.

SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that Litchfield Hills Research, a leading equity research firm has initiated coverage of with a 'Buy' rating and an $11.00 price target. This price target represents a significant premium over the company's current share price, highlighting the firm's confidence in S.

SHL Telemedicine Receives Buy Rating with $11.00 Price Target

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce that the full results of the Imperial College London TELE-ACS clinical trial have been selected for presentation at the prestigious American College of Cardiology's 24th Annual Scientific Session & Expo Late-Breaking Clinical Trials Sessions (ACC 24 LBCT) in Atla.

Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine's SmartHeart® Technology, to Be Presented at ACC 24

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce its participation as a platinum sponsor at the BMC Congress 2024 in Berlin, scheduled for January 30th to 31st. In a significant collaboration with BARMER, one of the leading public health insurance companies in Germany, insuring about 8.7 million individuals, SHL Te.

SHL Telemedicine and BARMER to Highlight Digital Patient Care at BMC Congress 2024

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions is pleased to announce the soft launch of the SmartHeart® membership program in the US, marking a significant step forward in at-home healthcare. This program, available at www.getsmartheart.com, is part of SHL's Direct-to-Consumer (D2C) initiative, offering a comprehensive subscription service tha.

SHL Telemedicine Introduces SmartHeart® Direct-to-Consumer Membership Plan in the US

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions is pleased to announce the establishment of a comprehensive network of cardiologists aimed at catering to the needs of its B2B clientele and supporting the Direct-to-Consumer (D2C) sales of its SmartHeart® technology across the US. A keystone of clinical cardiology, the electrocardiogram (E.

SHL Telemedicine Establishes US Nationwide Cardiology Network for ECG Interpretations and Telehealth Visits

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions is pleased to announce that it has made significant strides in preparing for initiation of Direct-to-Consumer (D2C) sales of its SmartHeart® technology in the US. Among the steps already taken, the company has made investments towards establishing the necessary logistics, administrative pla.

SHL Telemedicine Announces Advancements in its Direct-to-Consumer Strategy in the US

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce the initial results from the Mayo Clinic HELP-MI and the Imperial College London TELE-ACS trials, presented at the Vulnerable Plaque and Patient Meeting (VPM) 2023 (as previously announced). The initial findings from both trials, which focus on the application of SHL.

SHL Telemedicine's SmartHeart® Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--Regulatory News: SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) (“SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for half-year 2023, emphasizing stable revenues and strategic growth initiatives. In H1 2023, SHL maintained stable revenues while making significant strategic advancements across all operations. The Company made substantial invest.

SHL Announces Half-Year Results 2023 – Strategic Moves to Accelerate Growth

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that initial results from trials conducted by the Mayo Clinic (as part of a previously announced collaboration) and by Imperial College London will be featured in two upcoming presentations at the Imperial Vulnerable Plaque and Patient Meeting 2023 (VPM). Both trials.

SHL Telemedicine's SmartHeart® Technology to Take Center Stage at Upcoming VPM 2023 Conference

TEL AVIV, Israel, ZURICH and NEW YORK , Sept. 6, 2023 /PRNewswire/ --  SHL Telemedicine Ltd.

SHL Telemedicine: Half-year results 2023 and Conference Call Scheduled for September 21, 2023

Listing on the SIX Swiss Exchange to continue in parallel to the NASDAQ listing ZURICH and TEL AVIV , March 31, 2023 /PRNewswire/ -- SHL Telemedicine Ltd. ("SHL", SIX Swiss Exchange: SHLTN), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that the U.S. Securities and Exchange Commission (the "SEC") declared effective the Company's registration statement of its securities under the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), in connection with the NASDAQ Listing of its American Depositary Shares ("ADRs"), each representing one ordinary share of the Company.

News for SHL TeleMedicine Ltd Stock (SHLT)